Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)

#2698

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.

Aim(s): The purpose of this study was to assess the safety of PRRT beyond the recommended 4 cycles at mean 7.4GBq in patients with metastatic NET.

Materials and methods: Between 2007-2019, we treated 205 patients with PRRT. Eleven of those (7 males, mean age 55 years) had salvage PRRT, whom we retrospectively evaluated. They had progressive WHO GI/II NET (6 small bowel, 3 pancreas, 1 lung and 1 unknown primary). All 11 patients had disease control (partial response(PR)=6, stable disease(SD)=5) following initial PRRT. The median PFS after initial PRRT was 21 months (range:11-59 months). Toxicities and additional therapies were assessed from electronic records. Biochemical and radioimaging responses were documented. Progression free survival (PFS) and Overall survival (OS) analysis was performed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ghaleb N

Authors: Ghaleb N, Dick R, Heraghty N, Zwane-Allen P, Vadrucci M,

Keywords: Nuclear Medicine, Hybrid Imaging, Relapse Therapy, PRRT, Survival, Toxicity,

To read the full abstract, please log into your ENETS Member account.